Loading company…
Riskpilot
← Back to search
Sign in
Get full access
DENKRA AS
AS
Active
Org 929934547
Kirkegata 15, 3770 Kragerø
Manufacture of pharmaceutical preparations · NACE 2120
Est. 2022
0 employees
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2024
NOK 2,9M
EBITDA margin
72.4%
+24059% vs 2023
Equity ratio
72.5%
Financial strength
Net profit 2024
NOK 1,7M
+19080% vs 2023
EBITDA — year on year
NOK millions
0M
1M
1M
2M
3M
0M
2022
0M
0%
2023
2M
+200%
2024
Key figures
Annual report 2024
Revenue
NOK 2,9M
—
EBITDA
NOK 2,1M
+24059%
Net profit
NOK 1,7M
+19080%
Total assets
NOK 2,3M
+16422%
Equity
NOK 1,7M
+12837%
Employees
0
—
Company information
Legal name
DENKRA AS
Org number
929934547
Legal form
Aksjeselskap
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
27. september 2022
Share capital
NOK 30 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder alene.
Company purpose
Å drive utvikling, produksjon og handel med legemidler og andre varer samt annen tilknyttet virksomhet.
Contact
Address
Kirkegata 15, 3770 Kragerø
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Manufacture of pharmaceutical preparations
Companies in Kragerø
All Norway companies
Revenue
NOK millions
0M
1M
2M
3M
3M
0M
2022
0M
2023
3M
2024
EBITDA
NOK millions
0M
1M
1M
2M
2M
0M
2022
0M
2023
2M
2024
Income statement
NOK thousands
Item
2022
2023
2024
Revenue
0
0
2 945
Staff expenses
−0
−0
−0
EBITDA
−8
−9
2 132
Depreciation & amort.
−0
−0
−0
EBIT
−8
−9
2 132
Net financials
0
0
29
Profit before tax
−8
−9
2 160
Tax
−0
−0
472
Net profit
−8
−9
1 689
Balance sheet
NOK thousands
Item
2022
2023
2024
Total assets
22
14
2 346
Equity
22
13
1 702
Long-term debt
0
0
0
Short-term debt
0
1
644
Total debt
0
1
644
Financial ratios
5-year trend
EBITDA margin
72.4%
This company
15.8%
Market median
+358% vs market
2022
2024
Equity ratio
72.5%
This company
38.2%
Market median
+90% vs market
2022
2024
Return on equity
99.2%
This company
18.4%
Market median
+439% vs market
2022
2024
Net profit margin
57.3%
This company
8.1%
Market median
+607% vs market
2022
2024
Asset turnover
1.26×
This company
1.12×
Market median
+12% vs market
2022
2024
Debt / equity
0.38×
This company
0.62×
Market median
+39% vs market
2022
2024
Annual reports & filings
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Age
Other directorships
RS
Ragnar Salmen
Chief Executive Officer
Chief Executive Officer
2022
—
—
Board of directors
Non-executive oversight
Name
Role
Member since
Age
Other directorships
HL
Henrik Lund Uth
Chairman
2022
—
—
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Pharmore As
Company
45.0%
45.0%
2023
Inmedic Group As
Company
45.0%
45.0%
2023
Unknown
Individual
45.0%
45.0%
2022
Harald Ehnebom
Individual
5.0%
5.0%
2023
Hilde Kilen
Individual
5.0%
5.0%
2023
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of DENKRA AS also hold positions in
0
other companies.
Person
Role here
Other companies
Ragnar Salmen
Chief Executive Officer
0 companies
Henrik Lund Uth
Chairman
0 companies